{"filing":{"accession_number":"0001193125-26-380194","cik":"0001622229","ticker":"COGT","company_name":"Cogent Biosciences, Inc.","form":"8-K","filing_date":"2026-09-02","report_date":"2026-09-01","primary_document":"d184156d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1622229/000119312526380194/d184156d8k.htm"},"events":[{"id":31309,"run_id":28723,"accession_number":"0001193125-26-380194","anchor_item_number":"1.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Cogent Biosciences entered into a Commercial Supply Agreement with Hovione on September 1, 2026, to manufacture bezuclastinib spray-dried dispersion and bezuclastinib tablets. This is a material supply/manufacturing contract for the Company's product, with a five-year initial term and automatic renewals. While Item 1.01 typically covers M\u0026A activity, this is a supply agreement rather than an acquisition, disposition, or change of control; it is a material operational/commercial contract that does not fit the specific M\u0026A definition but is clearly material to the Company's business operations and product supply chain.","company_name":"Cogent Biosciences, Inc.","ticker":"COGT","filing_date":"2026-09-02","form":"8-K","submitted_at":null,"items":[{"id":34148,"accession_number":"0001193125-26-380194","item_number":"1.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Cogent Biosciences entered into a Commercial Supply Agreement with Hovione on September 1, 2026, to manufacture bezuclastinib spray-dried dispersion and bezuclastinib tablets. This is a material supply/manufacturing contract for the Company's product, with a five-year initial term and automatic renewals. While Item 1.01 typically covers M\u0026A activity, this is a supply agreement rather than an acquisition, disposition, or change of control; it is a material operational/commercial contract that does not fit the specific M\u0026A definition but is clearly material to the Company's business operations and product supply chain.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T20:13:38.105790+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34148,"accession_number":"0001193125-26-380194","item_number":"1.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Cogent Biosciences entered into a Commercial Supply Agreement with Hovione on September 1, 2026, to manufacture bezuclastinib spray-dried dispersion and bezuclastinib tablets. This is a material supply/manufacturing contract for the Company's product, with a five-year initial term and automatic renewals. While Item 1.01 typically covers M\u0026A activity, this is a supply agreement rather than an acquisition, disposition, or change of control; it is a material operational/commercial contract that does not fit the specific M\u0026A definition but is clearly material to the Company's business operations and product supply chain.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T20:13:38.105790+00:00","company_name":"Cogent Biosciences, Inc.","ticker":"COGT","filing_date":"2026-09-02"}]}